Skip to main content

Table 8 Literature verification of predicted direct compound-cardiovascular disease interactions

From: Development of simultaneous interaction prediction approach (SiPA) for the expansion of interaction network of traditional Chinese medicine

Predicted interactions Validated literatures
Borneol (C8)—Hyperlipidemia (D16) Borneol has ameliorative effect of hyperlipidemia in diabetic Wistar rats [32]
Cryptotanshinone (C10)—Diabetes mellitus type 2 (D20) Cryptotanshinone has effect of antidiabetes via activation of AMP-activated protein kinase [33]
Ginsenoside-Rg1 (C18)—Diabetes mellitus type 2 (D20) Ginsenoside-Rg1 can alleviate the insulin resistance through increasing the uptake of glucose and decreasing the output of glucose [34, 35]
Tanshinone IIA (C40)—Diabetes mellitus type 2 (D20) Tanshinone IIA may alleviate type 2 DM symptoms in experimental rats [36]
Cryptotanshinone (C10)—Obesity (D12) Cryptotanshinone promotes commitment to the brown adipocyte lineage and mitochondrial biogenesis in C3H10T1/2 mesenchymal stem cells to alleviate obesity [37]
Tanshinone IIA (C40)—Obesity (D12) Tanshinone IIA may treat obesity through PPARγ [38]
Tanshinone IIA (C40)—Angina pectoris (D18) Sodium tanshinone IIA silate can act as an add-on therapy in patients with unstable angina pectoris [39]
Ginsenoside-Rg1 (C18)—Acute Myocardial infarction (D1) Ginsenoside-Rg1 could enhance angiogenesis and ameliorates ventricular remodeling in a rat model of Acute Myocardial infarction [40]